Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so-familiar routine of meetings, deadlines, Skype calls, and the like has, of course, predictably returned. To cope, we are brewing the usual number of cups of stimulation — actually, we have lost count — as we dig in for another busy day. On that note, here are a few tidbits to get you going. We hope your day goes well and, as always, please do keep in touch.

A new coalition of Fortune 500 companies called EmployersRx is hoping to push lawmakers to start thinking about drug pricing policies that will affect the broadest number of Americans, not just changes to federal programs, STAT writes. Called EmployerRx, the group has not formally endorsed the House Democratic bill that would give Medicare a chance to buy drugs at negotiated prices, but its coy position is a startling departure from the rest of the business community, which has blasted the bill as socialist and bad for business.


Children and teenagers with severe, sometimes life-threatening peanut allergies can reduce their risk from accidental exposure with a new treatment approved Friday by the Food and Drug Administration, STAT reports. But administering the new treatment, called Palforzia and made by Aimmune Therapeutics (AIMT), is cumbersome and carries its own safety risks, which may deter families and allergists from using it. Critics say Palforzia is more likely to be a niche treatment given its tolerability and side effect issues. And the cost is about $10,680 a year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!